Watch blood DNA for early breast cancer return, then add palbociclib
Treatments studied
Part of Cancer clinical trials.
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ER-positive and HER2-negative breast cancer confirmed by a pathology report
- Your cancer was considered high-risk early stage, or it was treated with certain chemo/endocrine approaches before surgery
- You have had surgery with clear margins and scans show no visible spread or incurable local disease
- You are able to provide stored tumor tissue and take frequent blood samples
- You have been on standard hormone therapy for at least 6 months (up to 7 years) with an extra 3 years planned
- Your general health labs and heart/lung health are adequate, and you can take oral study medicine safely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
This study uses a simple blood test (liquid biopsy) along with imaging scans to look for early signs that triple-negative breast cancer may have returned in patients who still had cancer after chemo. It aims to catch a possible recurrence sooner, which could help guide earlier treatment.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.